Cargando…

A TP53-based immune prognostic model for muscle-invasive bladder cancer

Background: Muscle-invasive bladder cancer (MIBC) patients are subject to unfavorable treatment options and a high recurrence rate. The status of TP53 mutations played an essential role in the progression and the prognosis of MIBC. The present study proposed to investigate the association between TP...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Hongyan, Lu, Huayi, Cui, Wanli, Huang, Yufan, Jin, Xuefei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals 2020
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7880361/ https://www.ncbi.nlm.nih.gov/pubmed/33323544 http://dx.doi.org/10.18632/aging.202150

Ejemplares similares

A TP53-Associated Immune Prognostic Signature for the Prediction of Overall Survival and Therapeutic Responses in Muscle-Invasive Bladder Cancer
por: Wu, Xiangkun, et al.
Publicado: (2020)

Coexistence of YWHAZ amplification predicts better prognosis in muscle-invasive bladder cancer with CDKN2A or TP53 loss
por: Liu, Shenghua, et al.
Publicado: (2016)

Significance of TP53 and immune-related genes to prostate cancer
por: Huang, Hang, et al.
Publicado: (2021)

Development and validation of a TP53-associated immune prognostic model for hepatocellular carcinoma
por: Long, Junyu, et al.
Publicado: (2019)

Individualized prognosis stratification in muscle invasive bladder cancer: A pairwise TP53-derived transcriptome signature
por: Liu, Hua-Ping, et al.
Publicado: (2023)

TP53 codon 72 polymorphism is associated with FGFR3 and RAS mutation in non-muscle-invasive bladder cancer
por: Kawahara, Takashi, et al.
Publicado: (2019)

Gene Expression Analyses in Non Muscle Invasive Bladder Cancer Reveals a Role for Alternative Splicing and Tp53 Status
por: Dueñas, Marta, et al.
Publicado: (2019)

Development of prognostic signature based on immune-related genes in muscle-invasive bladder cancer: bioinformatics analysis of TCGA database
por: Jin, Kun, et al.
Publicado: (2021)

Prognostic value of LAMP3 and TP53 overexpression in benign and malignant gastrointestinal tissues
por: Sun, Rongwei, et al.
Publicado: (2014)

Specific TP53 subtype as biomarker for immune checkpoint inhibitors in lung adenocarcinoma
por: Sun, Hao, et al.
Publicado: (2020)

Alterations in TP53 Are a Potential Biomarker of Bladder Cancer Patients Who Benefit From Immune Checkpoint Inhibition
por: Lyu, Qiong, et al.
Publicado: (2020)

Deletions of 9p21 and TP53 in bladder cancer.
por: Park, W. S., et al.
Publicado: (1996)

Prognostic value genotypes and LOH at TP53 codon 72 and TP53 mutations in primary breast cancer
por: Kyndi, M, et al.
Publicado: (2005)

Construction and Validation of an Immune-Related Prognostic Model Based on TP53 Status in Colorectal Cancer
por: Zhao, Xiaojuan, et al.
Publicado: (2019)

Establishing an 8‐gene immune prognostic model based on TP53 status for lung adenocarcinoma
por: Wu, Guodong, et al.
Publicado: (2022)

Prognostic significance of TP53 alterations in breast carcinoma.
por: Andersen, T. I., et al.
Publicado: (1993)

Identification of an immune-related long non-coding RNA signature and nomogram as prognostic target for muscle-invasive bladder cancer
por: Song, Yuxuan, et al.
Publicado: (2020)

Analysis of TP53 gene and particular infrastructural alterations in invasive ductal mammary carcinoma
por: Mihalcea, Corina Elena, et al.
Publicado: (2020)

Mitigating the Risk of t-MNs Development: TP53 or Not TP53?
por: Tesio, Melania
Publicado: (2023)

The TP53 website: an integrative resource centre for the TP53 mutation database and TP53 mutant analysis
por: Leroy, Bernard, et al.
Publicado: (2013)

Immune landscape and a promising immune prognostic model associated with TP53 in early‐stage lung adenocarcinoma
por: Wu, Chengde, et al.
Publicado: (2020)

Impairment of rigidity sensing caused by mutant TP53 gain of function in osteosarcoma
por: Luo, Ming, et al.
Publicado: (2023)

Clinical and prognostic implications of an immune‐related risk model based on TP53 status in lung adenocarcinoma
por: Song, Xuming, et al.
Publicado: (2021)

Molecular characterization of AML‐MRC reveals TP53 mutation as an adverse prognostic factor irrespective of MRC‐defining criteria, TP53 allelic state, or TP53 variant allele frequency
por: Zhao, Davidson, et al.
Publicado: (2022)

Intronic TP53 Polymorphisms Are Associated with Increased Δ133TP53 Transcript, Immune Infiltration and Cancer Risk
por: Eiholzer, Ramona A., et al.
Publicado: (2020)

Significance of TP53 mutation in bladder cancer disease progression and drug selection
por: Wu, Guang, et al.
Publicado: (2019)

Prediction of TP53 mutations by p53 immunohistochemistry and their prognostic significance in gastric cancer
por: Hwang, Hye Jung, et al.
Publicado: (2020)

The prognostic values of the expression of Vimentin, TP53, and Podoplanin in patients with cervical cancer
por: Lin, Jiaying, et al.
Publicado: (2017)

TP53 and TP53-associated genes are correlated with the prognosis of paediatric neuroblastoma
por: Wang, Haiwei, et al.
Publicado: (2022)

A TP53 Related Immune Prognostic Model for the Prediction of Clinical Outcomes and Therapeutic Responses in Lung Adenocarcinoma
por: Zhang, Xiaonan, et al.
Publicado: (2022)

Immunohistochemical correlates of TP53 somatic mutations in cancer
por: Murnyák, Balázs, et al.
Publicado: (2016)

Nanocomplex-based TP53 gene therapy promotes anti-tumor immunity through TP53- and STING-dependent mechanisms
por: Moore, Ellen C., et al.
Publicado: (2018)

TP53_PROF: a machine learning model to predict impact of missense mutations in TP53
por: Ben-Cohen, Gil, et al.
Publicado: (2022)

TP53 codon 72 Polymorphism and bladder cancer risk: a meta-analysis and emphasis on the role of tumor or smoking status
por: Zhang, Lei, et al.
Publicado: (2018)

Optimisation of TP53 reporters by systematic dissection of synthetic TP53 response elements
por: Trauernicht, Max, et al.
Publicado: (2023)

The prognostic value of TP53 mutations in hypopharyngeal squamous cell carcinoma
por: Omura, Go, et al.
Publicado: (2017)

TP53/BRAF mutation as an aid in predicting response to immune-checkpoint inhibitor across multiple cancer types
por: Cao, Jia-Zheng, et al.
Publicado: (2022)

Prognostic value of the systemic immune-inflammation index in non-muscle invasive bladder cancer
por: Katayama, Satoshi, et al.
Publicado: (2021)

Genetic Variation in the TP53 Pathway and Bladder Cancer Risk. A Comprehensive Analysis
por: Pineda, Silvia, et al.
Publicado: (2014)

MDM4 expression as an indicator of TP53 reactivation by combined targeting of MDM2 and MDM4 in cancer cells without TP53 mutation
por: Hirose, Mitsuaki, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_lm6m0on5p608rmve7top2pf5nr